The Honorable Q. Todd Dickinson  
Director of U.S. Patent and Trademark Office  
Commissioner for Patents  
Box Pat. Ext.  
Washington, D.C. 20231

Dear Director Dickinson:

This is in regard to the application for patent term extension for U.S. Patent No. 4,418,068, filed by Eli Lilly and Company, under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Evista, the human drug product claimed by the patent.

The total length of the regulatory review period for Evista is 5,412 days. Of this time, 5,228 days occurred during the testing phase and 184 days occurred during the approval phase. These periods of time were derived from the following dates:

1. **The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective:** February 16, 1983.

   FDA has verified the applicant's claim that the date the investigational new drug application became effective was on February 16, 1983.

2. **The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act:** June 9, 1997.

   FDA has verified the applicant's claim that the new drug application (NDA) for Evista (NDA 20-815) was initially submitted on June 9, 1997.

3. **The date the application was approved:** December 9, 1997.

   FDA has verified the applicant's claim that NDA 20-815 was approved on December 9, 1997.
This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: James J. Sales
Eli Lilly and Company
Patent Division/JJS
Lilly Corporate Center
Indianapolis, IN 46285